Abstract:Currently, amino-terminal PEGylated human granulocyte colony stimulating factor (huG-CSF) is used to prevent and treat neutropenia. Although huG-CSF has been used as a drug for more than 20 years, it has three significant drawbacks: (i) it relies on PEG aldehyde for PEGylation of the alpha-amino group of the first amino acid, and this leads to non-specific PEGylation of the epsilon amino group of lysine residues within the G-CSF; (ii) longer-acting G-CSF variants are desirable to reduce the risk of chemotherapy-associated neutropenia; and (iii) G-CSF cannot be administered on the day of chemotherapy. In an attempt to overcome the above drawbacks, we engineered cysteine variants of G-CSF to facilitate the maleimide PEG-based site-specific PEGylation that leads to a highly homogenous PEGylated product. Importantly, we have demonstrated that 20 kDa thiol-reactive PEG conjugated by maleimide chemistry to the Cys2 G-CSF variant exhibits leukocyte proliferative activity similar to that of the commercially available G-CSF conjugated with aldehyde PEG in a neutropenia mice model. Moreover, we have demonstrated that PEGylation of the cysteine variant of huG-CSF with higher molecular weight PEGs, such as 30 kDa PEG and 40 kDa PEG, leads to significantly prolonged leukocyte proliferation activity compared to the variant conjugated with 20 kDa PEG. Importantly, even a half-dose of the engineered variant conjugated with 40 kDa PEG exhibited significantly longer biological activity than the commercially available 20 kDa PEGylated huG-CSF. Finally, we have demonstrated that administration of the engineered variant conjugated with 40 kDa PEG on the day of administration of cyclophosphamide for inducing neutropenia in mice can alleviate neutropenia through leukocyte proliferation. In summary, this study provides the design of site-specific PEGylated huG-CSF variants with improved therapeutic potential. It opens the possibility of long-acting and same-day prophylactic administration of G-CSF after chemotherapy drug regimens. These results may pave the way for the development of potential G-CSF derivatives possessing longer half-lives and favorable clinical attributes.

Study on rhG-CSF modified with polyethylene glycol]

Chemical Modification of Activated Polyethylene Glycol to Lysozyme and Granulocyte Colony-Stimulating Factor

Pharmacokinetics of PEG-rhG-CSF and rHSA-hG-CSF in mice determined with ELISA

[Study of Target Pegylated Recombinant Mutant Human Granulocyte Colony Stimulating Factor].

Engineering a Pharmacologically Superior Form of Granulocyte-Colony-stimulating Factor by Fusion with Gelatin-Like-protein Polymer.

Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study

Preparation and Characterization of Site-Specific Fatty Chain-Modified Recombinant Human Granulocyte Colony Stimulating Factor

Development of Site-Specific PEGylated Granulocyte Colony Stimulating Factor With Prolonged Biological Activity

Surface Biofunctionalization of Gadolinium Phosphate Nanobunches for Boosting Osteogenesis/Chondrogenesis Differentiation

Characterization of a Long-Acting Site-Specific PEGylated Murine GM-CSF Analog and Analysis of Its Hematopoietic Properties in Normal and Cyclophosphamide-Treated Neutropenic Rats

Study on preparation and purification of PEGylated β-lactoglobulin

Modulation of protein aggregation by polyethylene glycol conjugation: GCSF as a case study

An assessment of the pharmacokinetics, pharmacodynamics, and tolerability of GCPGC, a novel pegylated granulocyte colony-stimulating factor (G-CSF), in healthy subjects

In vivo pharmacokinetics and pharmacodynamics of positional isomers of mono-PEGylated recombinant human granulocyte colony stimulating factor in rats

Development and Characterization of a Novel Fusion Protein of a Mutated Granulocyte Colony-Stimulating Factor and Human Serum Albumin in Pichia Pastoris.

Advantages of Prophylactic PEG-rhG-CSF Versus Rhg-Csf in Breast Cancer Patients Receiving Multiple Cycles of Myelosuppressive Chemotherapy: an Open-Label, Randomized, Multicenter Phase Ⅲ Study.

Preparation and Characterization of Poly(ethylene Glycol)-G-chitosan with Water- and Organosolubility

[Phase I clinical trail of intravenous pegylated recombinant human granulocyte colony-stimulating factor]

Synthesis and Characterization of Glucosamine Modified Poly(ethylene Glycol) Hydrogels Via Photopolymerization

Pharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF mutant (Ro 25-8315) in healthy volunteers: comparison with single and multiple daily doses of filgrastim

Efficient preparation and PEGylation of recombinant human non-glycosylated erythropoietin expressed as inclusion body in E. coli